https://www.oncologynurseadvisor.com Wed, 07 Feb 2024 17:15:46 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png https://www.oncologynurseadvisor.com 32 32 https://www.oncologynurseadvisor.com/home/cancer-types/lymphoma/plasmablastic-lymphoma-challenge-treat-poor-prognostic-factors-treatment/ Wed, 07 Feb 2024 15:20:00 +0000 https://www.oncologynurseadvisor.com/?p=116553 https://www.oncologynurseadvisor.com/home/cancer-types/leukemia/chronic-leukemia-cll-venetoclax-anti-cd20-monoclonal-antibody-treatment/ Wed, 24 Jan 2024 15:20:00 +0000 https://www.oncologynurseadvisor.com/?p=116173 https://www.oncologynurseadvisor.com/home/cancer-types/lymphoma/lymphoma-brentuximab-vedotin-dacarbazine-nivolumab-viable-option/ Thu, 04 Jan 2024 15:20:00 +0000 https://www.oncologynurseadvisor.com/?p=115301 https://www.oncologynurseadvisor.com/home/cancer-types/general-oncology/children-pain-cancer-home-monitoring-app-improved-outcomes-treatment/ Wed, 20 Dec 2023 15:40:00 +0000 https://www.oncologynurseadvisor.com/?p=115037 Researchers determined use of a home pain monitoring app led to less clinically significant pain in children with cancer.]]> https://www.oncologynurseadvisor.com/home/cancer-types/multiple-myeloma/multiple-myeloma-equecabtagene-autoleucel-durable-response-treatment-risk/ Thu, 19 Oct 2023 13:30:00 +0000 https://www.oncologynurseadvisor.com/?p=113489 A substantial, long-lasting response can be achieved in patients with relapsed/refractory multiple myeloma (RRMM) using equecabtagene autoleucel (equel-cel).]]>